Group 1 - BullFrog stock is experiencing a significant surge, trading 17.17% higher at $1.23 [5] - The company has entered into an agreement with a top pharmaceutical company to utilize its AI platform for accelerating drug discovery and clinical development for major depressive disorder (MDD) [2] - The collaboration is seen as third-party validation of BullFrog's proprietary capabilities and may expand into additional areas of the partner's research and development portfolio [3] Group 2 - The agreement provides exclusive access to a target candidate identified through BullFrog's analytical AI platform [2] - BullFrog's integrated platforms, including bfLEAP, bfPREP, and bfARENAS, leverage causal network inference to assist drug developers in identifying and prioritizing targets for complex diseases like MDD [3] - Further details regarding the agreement will be disclosed in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission [4]